

1 **The impact of early anti-SARS-CoV-2 antibody production on the length of**
2 **hospitalization stay among COVID-19 patients.**

3

4 Dalziza Victalina de Almeida ^{1*}, Priscila Alves Cezar ¹, Thais Freitas Barreto Fernandes
5 ¹, Marcos Gustavo Araujo Schwarz ², Leila Mendonça-Lima ², Carmem Beatriz Wagner
6 Giacoia-Gripp ¹, Fernanda Heloise Côrtes ¹, Monick Lindenmeyer Guimarães ¹, Jose
7 Henrique Pilotto ¹, Nathalia Beatriz Ramos de Sá ¹, Andressa da Silva Cazote ¹, Larissa
8 Rodrigues Gomes ³, Marcel de Souza Borges Quintana ⁴, Marcelo Ribeiro-Alves ⁵, Lara
9 Coelho ⁵, Kim Mattos Geraldo ⁵, Maria Pia Diniz Ribeiro ⁵, Sandra Wagner Cardoso ⁵,
10 Beatriz Gilda Jegerhom Grinsztejn ⁵, Valdiléa Gonçalves Veloso dos Santos ⁵, Mariza
11 Gonçalves Morgado ¹

12

13 1 Laboratory of AIDS & Molecular Immunology, Oswaldo Cruz Institute, FIOCRUZ, Rio
14 de Janeiro, Brazil.

15

16 2 Laboratory of Functional Genomics and Bioinformatics, Instituto Oswaldo Cruz,
17 Fiocruz, Rio de Janeiro, Brazil.

18

19 3 Center of Technological Development in Health (CDTS)/National Institute of Science
20 and Technological for Innovation on Neglected population diseases (INCT-IDPN),
21 FIOCRUZ, Rio de Janeiro

22

23 4 Clinical Research Platform, Evandro Chagas National Institute of Infectious Diseases,
24 FIOCRUZ, Rio de Janeiro, RJ, Brazil

25

26 5 Laboratory of Clinical Research on STD/AIDS, National Institute of Infectology Evandro
27 Chagas, FIO-CRUZ, Rio de Janeiro

28

29 *Correspondence: Dalziza Victalina de Almeida - Address: Laboratory of AIDS &
30 Molecular Immunology, Oswaldo Cruz Institute, FIOCRUZ. Av. Brazil 4365, Leonidas
31 Deane Building, Room 401, Rio de Janeiro, Brazil. 21040-360 - E-mail:
32 dalziza@gmail.com Tel: +55-21-38658227 - Fax: +55-21-38658173.

33

34 **Abstract:**

35 COVID-19 has challenged the scientific community in the search for biological
36 markers and information that can contribute to the early management of the
37 severe disease. Given the global scale of COVID-19, including reports of
38 reinfection even in the presence of effective vaccines, we have not yet been able

39 **to eradicate the disease. This factor implies the emergence of new waves and an**

40 increasing number of hospitalizations. This study aimed to characterize the
41 neutralizing antibody (Nab) geometric mean titers (GMTs) in hospitalized patients
42 with COVID-19 and to evaluate the association with length of stay, comorbidities,
43 and patient outcome. Among the 103 participants, 84 (81.5%) had some previous
44 condition associated with worsening health, and 31 (30%) died. We found that
45 neutralization potency varied greatly across individuals and was significantly
46 higher in patients discharged before 14 days than in patients who stayed longer
47 in the hospital. During the study period, 15 people living with HIV (PLWH) were
48 hospitalized, and no significant difference in clinical characteristics or anti-SARS-
49 CoV-2 Nabs was observed. However, PLWH with severe COVID-19 were
50 younger (41.7, IQR=17.5) than other hospitalized COVID-19 patients (59.3,
51 IQR=22, $P < 0.01$). A high anti-HIV-1 antibody GMT of 583.9 (95% CI: 344-990)
52 was detected, demonstrating maintenance of anti-HIV-1 Nab production among
53 PLWH coinfecting with SARS-CoV-2. Therefore, these results indicate that
54 neutralizing antibodies are not the only immunological response capable of
55 controlling disease progression. Nevertheless, these data highlight the
56 importance of more Nab screening studies to predict shorter hospital stays.

57

58 **Keywords:** Neutralizing Antibodies; pseudovirus; SARS-CoV-2; HIV-1; PLWH;
59 COVID-19

60

61 **1. Introduction**

62 The major portal of SARS-CoV-2 entry into host cells is through the respiratory
63 tract, with the virus binding to the angiotensin-converting enzyme 2 (ACE-2)
64 receptor on alveolar type 2 (AT2) cells in the epithelium. When attacked by the

65 virus, AT2 cells produce inflammatory mediators, stimulating proinflammatory
66 chemokine production and initiating immunoglobulin production (1). Generally,
67 immunoglobulin production occurs 4 days after the onset of symptoms, enabling
68 the diagnosis of COVID-19 through specific SARS-CoV-2 antibodies (2). The
69 detection of neutralizing antibodies (Nabs) against SARS-CoV-2 helps to
70 evaluate the status of the immune response of asymptomatic/symptomatic
71 COVID-19 patients and severe COVID-19, in addition to indicating protection
72 correlates (3).

73 Recent studies have demonstrated that the magnitude of Nab responses appears
74 to correlate with viral load, with higher responses reported among patients with
75 more severe disease and older adults (4, 5). Several comorbidities, including
76 respiratory disease, hypertension, diabetes, kidney disease, and HIV-1 infection,
77 have been identified as risk factors associated with severe COVID-19
78 manifestation (6). Nonetheless, few studies describing the anti-SARS-CoV-2 Nab
79 response in HIV/COVID-19 coinfections have been performed thus far (7). The
80 identification and characterization of Nabs can help prevent new infections in
81 exposed individuals, and passive immunization can be used as a treatment
82 against disease progression to severe forms (8, 9).

83 The main objective of this study was to provide preliminary data on the Nab
84 immune response to SARS-CoV-2 in a group of hospitalized subjects with
85 COVID-19 in Rio de Janeiro, Brazil, including those with COVID-19 associated
86 with HIV-1 infection. For this, we calculated the seroconversion rate of SARS-
87 CoV-2 Nabs using the pseudovirus neutralization assay (PNA) (10) for a cohort
88 of 103 hospitalized COVID-19 patients with or without HIV-1-associated infection
89 and evaluated its association with clinical features of COVID-19.

90 **2. Materials and Methods**

91 **Human samples**

92 Plasma samples analyzed in this study were obtained from a clinical COVID-19
93 follow-up study that included moderate/severe hospitalized patients at the
94 COVID-19 Pandemic Hospital Center INI/FIOCRUZ, Rio de Janeiro, Brazil,
95 between June 2020 and May 2021 (RECOVER-SUS study-NCT04807699). A
96 total of 103 hospitalized participants who tested positive for SARS-CoV-2 by
97 nasopharyngeal sampling using RT–PCR were selected. Plasma samples were
98 collected on the first day of hospitalization (D1), after 14 days (D14), and between
99 seven and eleven months (D300) after hospital discharge. None of the patients
100 were vaccinated for COVID-19 during the blood collection period. The local ethics
101 committee approved this study, and all participants signed an informed consent
102 form; all the samples were deidentified.

103 **Cells**

104 HEK293T-ACE2 and HEK293T/17 cells were cultured in DMEM with 10% fetal
105 bovine serum (FBS), 2 mM of L-glutamine, and 200 µg/mL of hygromycin B
106 (Thermo Fisher Scientific, US) at 37 °C with 5% CO₂. HEK293T-ACE2 cells were
107 a donation from BEI resources (BEI catalog number NR-52511), and the T2M-bl
108 cell line was obtained through the NIH AIDS Research and Reference Reagent
109 Program.

110 **Pseudovirus production and titration**

111 All transfections were performed in T75 culture flasks, and the pseudovirus was
112 produced in HEK293T/17 cells cultured 24 hours before reaching 50%–70%
113 confluence on the day of the experiment. Viral particles were produced using the
114 Luciferase-IRES-ZsGreen backbone obtained from the BEI resource, which was

115 established by Crawford et al., 2020 (10). Briefly, 1 µg of HDM-IDTS pike-fixK
116 (BEI catalog number NR-52514), 6 µg of pHAGE-CMV-Luc2-IRES-ZsGreen-W
117 (BEI catalog number NR-52516), 1.4 µg of HDM-Hgpm2 (BEI catalog number
118 NR-52517), 1.4 µg of HDM-tat1b (NR-52518) and 1.4 µg of pRC-CMV-Rev1b
119 (NR-52519) were used and cotransfected with Lipofectamine 3000 (Thermo
120 Fisher Scientific, US) and Opti-MEM I Reduced Serum Medium (Gibco) was
121 used, as well. For the positive control, VSV G-pseudotyped lentiviral particles with
122 the ZsGreen backbone were produced using the plasmid pHEF expressing
123 vesicular stomatitis virus (VSV-G), obtained from the NIH-HIV Reagent Program
124 (catalog number RP-4693). Pseudovirus supernatants were collected
125 approximately 72 h post-transfection, and the FBS concentration in the virus-
126 containing culture medium was adjusted to 20% (i.e., for each 1 ml of virus
127 harvested, 0.125 ml of FBS was added), filtered through a 0.45-µm filter, and
128 stored at -80 °C.

129 For median tissue culture infectious dose (TCID₅₀) assay measurements, 293T-
130 ACE-2 cells (4 x 10⁴ cells in 100 µL of growth medium/well) were added to each
131 well, followed by 20 mg/ml of DEAE-dextran with 11 pseudovirus dilutions, added
132 after 24 h. Serial 5-fold dilutions of pseudovirus were quadruplicated in 96-well
133 culture plates in a volume of 100 µL of growth medium/well. After 48 h of
134 incubation (37 °C in 5% CO₂), 100 µL of culture medium was removed from each
135 well, and 100 µL of Britelite Plus Reagent (PerkinElmer) was added to the cells.
136 After 2 min of incubation at room temperature to allow cell lysis, 150 µL of the cell
137 lysate was transferred to black, solid 96-well plates for luminescence
138 measurements using a GloMax® Navigator Microplate Luminometer (Promega,
139 US). Wells with pseudovirus SARS-CoV-2-containing supernatant that was not

140 toxic to the cells based on light microscopy inspection, and that produced at least
141 relative luminescence units (RLU) 10 times greater than the background were
142 scored as positive. The TCID₅₀ was calculated using the Reed–Muench method
143 and using the macro described on the TCID₅₀; the cutoff macro is available on
144 the Los Alamos HIV Immunology Database
145 (<https://www.hiv.lanl.gov/content/nab-reference-strains/html/home.htm>).

146 **Pseudovirus Neutralization Assay**

147 Neutralization activity was expressed as Nab titers, defined as the interpolated
148 plasma dilution that produced a 50% reduction in virus infectivity or a 50% (ID₅₀)
149 and 90% inhibitory dose (ID₉₀), observed as reductions in Luciferase reporter
150 gene expression after a single round of virus infection of 293T-ACE-2 cells, given
151 that some components essential for viral replication or persistent infection were
152 deleted from the genome. For each sample, residual infection was estimated
153 across eight serum dilutions ranging from 1:20 to 1:4,3740; 3-fold serial dilutions
154 of samples were performed in duplicate (96-well flat bottom plate) in DMEM
155 growth medium (100 µL/well). An amount of virus to achieve a TCID₅₀ of 100 000
156 RLU equivalents was added to each well in a volume of 50 µL. The plates were
157 then incubated for 90 min at 37 °C in a total volume of 150 µL of growth medium.
158 293T-ACE-2 cells (4 x 10⁴ cells in 100 µL of growth medium) were added to each
159 well, and after 24 h, 20 mg/ml of DEAE-dextran was added. The normalized %
160 inhibition was calculated using uninfected cells (100% inhibition), and as a
161 negative control, we used prepandemic plasma (0% inhibition) as a reference.
162 For specificity, we used anti-SARS coronavirus recombinant human IgG1 (BEI
163 catalog number: NR-52392). After 48 h of incubation, 150 µL of culture medium
164 was removed from each well, and 100 µL of Britelite reagent (PerkinElmer, US)

165 was added to the cells. After 2 min of incubation at room temperature to allow cell
166 lysis, 150 μ L of the cell lysate was transferred to black, solid 96-well plates for
167 luminescence measurements using a GloMax® Navigator Microplate
168 Luminometer (Promega, US). The assays were evaluated as having passed
169 when the following parameters were met: the mean RLU of the virus control was
170 10 x higher than the background of the cell control; and the standard deviation of
171 RLU in the virus control well was 30%. All data were analyzed using Excel Macros
172 Nab analysis provided by the Global HIV Vaccine Enterprise, available on the Los
173 Alamos HIV Immunology Database ([https://www.hiv.lanl.gov/content/nab-
174 reference-strains/html/home.htm](https://www.hiv.lanl.gov/content/nab-reference-strains/html/home.htm)).

175 **Statistical analysis**

176 Nonparametric Mann–Whitney U tests were used to compare continuous
177 numerical baseline demographic and clinical variables, whereas Fisher's exact
178 tests were used for categorical variables. Multiple linear fixed effects models were
179 used to evaluate patient differences related to clinical outcome (discharge or
180 death) and HIV-1 serology. The model's fixed systematic component was
181 adjusted by confounding variables (age, sex, self-declared race, number of
182 comorbidities, and days since first symptoms of COVID-19 at hospital admission).
183 The mean and 95% confidence intervals (95% CIs) were used, and the results
184 were also presented graphically for the estimated mean marginal effects, where
185 all other variables included in the multiple linear fixed models remained in equal
186 proportions or their average values, and contrasts were constructed from these
187 estimated mean marginal effects. For each parameter (Figure 1), a
188 nonparametric ANOVA (Sidak's multiple comparisons test) was performed.
189 Tukey's honest significant difference (HSD) method was used to correct p values

190 by the number of comparisons whenever applicable (Figure 2). R software
191 (<https://www.r-project.org/about.html>) version 4.1.1 packages 'lme4', 'emmeans',
192 and their dependencies were used to perform the statistical analyses. For each
193 parameter, a nonparametric ANOVA was performed, and a paired t test was
194 performed to compare Nab titers (Figures 3 and 4). To evaluate the continuous
195 ID₅₀ and ID₉₀ outcomes, we used a simple linear regression model assuming
196 normal distribution for these outcomes on the log scale. Statistical significance
197 was declared at a *p value* ≤0.05. Analysis was performed with statistical
198 computing software GraphPad Prism 9.

199 **3. Results**

200 **3.1. Characteristics of the study population**

201 Plasma samples from 103 hospitalized participants were analyzed for Nab
202 response to SARS-CoV-2. Sociodemographic and clinical data were collected for
203 the present study on the first day of hospital admission. Participants were
204 categorized according to the length of hospitalization into short hospitalization
205 (less than 14 days) and long hospitalization (over 14 days) groups to correlate
206 sociodemographic characteristics (Table 1) and clinical data (Table 2). Skin color,
207 age, and sex were not significantly distinct between the short and long
208 hospitalization groups, but 71 (68.9%) participants self-declared that they had
209 brown skin. Most patients were male (57 (55.3%)), and the mean age was 57.27
210 (IQR=23.51) years (Table 1).

211 The most common symptoms observed were fever, cough, chest pain, coryza,
212 dyspnea, anosmia, ageusia, diarrhea, abdominal pain, nausea, headache,
213 myalgia, and oxygen saturation below 95%. The presence of these symptoms
214 varied among the participants, with dyspnea symptoms being the most frequent

215 among the participants (74%), followed by oxygen saturation below 95% (37.5%)
216 and myalgia (21%). We observed that most individuals required oxygen (80.6%)
217 and remained hospitalized for longer periods, $P < 0.01$ (Table 2). Major
218 comorbidities included hypertension (49 (47.1%)), diabetes mellitus (33 (31.7%)),
219 and myalgia (22 (21.2%)). Other comorbidities were present in less than 20% of
220 the participants.

221 Among the individuals included in this study, 15 (14.4%) tested positive for HIV-
222 1 infection (PLWH). Of them, 9 (60%) were male, 14 (93.3%) self-declared having
223 brown skin, and none had obesity, anosmia, loss of taste, nausea, previous
224 stroke, heart failure, or coronary or rheumatic disease. Only 3 (20%) PLWH had
225 systemic arterial hypertension (SAH), which was different from the group without
226 HIV infection, where the majority, 54.1%, had this comorbidity ($P=0.02$). The
227 mean age of patients hospitalized with COVID-19 was 57.27 years. However,
228 among PLWH/people with COVID-19, the mean age was 41.7 years (IQR=17.5),
229 and among those with only COVID-19, the mean age was 59.3 years (IQR=22;
230 $P < 0.01$).

231 **3.2 Early humoral immune responses among hospitalized patients with** 232 **severe COVID-19**

233 Humoral anti-SARS-CoV-2 immune responses were assessed at study entry for
234 COVID-19 patients with severe disease. We noted variable levels of Nab anti-
235 SARS-CoV-2 ID₅₀ in their plasma samples collected on the first day of
236 hospitalization, corresponding to approximately nine days after the onset of the
237 first symptoms. Two patients (1.9%) had very high titers of Nabs (ID₅₀) of 1:11,532
238 and 1:14,962, 17 (16.5%) had high neutralization titers, between 1:500 and
239 1:10,000 Nab ID₅₀, whereas 72 (70%) of the patients developed Nab titers

240 between 1:500 and 1:20. Twelve patients (11.6%) had Nab titers under the
241 detectable limit of the assay (<1:20). Therefore, approximately 88% of COVID-19
242 patients exhibited robust neutralization of SARS-CoV-2 PNA at hospitalization.
243 Patients who had detectable production of Nabs were hospitalized on average
244 for less time (17 days) than those who did not have detected Nabs (27 days),
245 $P=0.0363$.

246 As expected, the VSV-G pseudotyped virus control showed the highest infectivity
247 for all samples at a 1:20 dilution.

248 **3.3 Association between anti-SARS-CoV-2 neutralizing antibodies and the** 249 **clinical condition of COVID-19 patients**

250 Interestingly, we found that although the mean age of the patients included in this
251 study, we observed that 18 patients were between 18 and 39 years of age, and
252 of these, 13 (72%) were hospitalized for more than 14 days. The clinical aspects
253 of this youngest group with longer hospitalization were evaluated. Twelve
254 (92.3%) declared themselves as having black skin color, and none of them had
255 comorbidities such as stroke, cardiac insufficiency, coronary artery disease,
256 active cancer, chronic kidney disease or dialysis, rheumatic diseases, dementia,
257 obesity or previous bariatric surgery, hepatic cirrhosis or transplant. However, six
258 (46%) of them were PLWH, and one of them also had active tuberculosis. The
259 Nab geometric mean titer (GMT) ID_{50} in this youngest group of patients
260 hospitalized for more than 14 days measured at study entry was 148 (95% CI:
261 56-387), while the GMT of young people hospitalized for less than 14 days was
262 360 (95% CI: 83-1,553).

263 Considering the COVID-19 discharge (n=69) or death (n=34) outcomes in our
264 study group, we observed that the GMT of anti-SARS-CoV-2 Nabs among

265 patients with a death outcome was 140 (95% CI: 74-263), whereas a Nab GMT
266 of 254 (95% CI: 170-380) was observed for those with a discharge outcome.
267 Hospitalization time was longer for patients who died (22; 95% CI: 15-29 days)
268 than for those who were discharged (16; 95% CI: 13-19 days), $P=0.040$. Of the
269 69 COVID-19 patients who were discharged, 7 (10%) had no Nab response on
270 D1 and were hospitalized for an average time of 20 (95% CI: 10-30) days. Of the
271 34 patients who died, 5 (14%) had no Nab on D1 and were hospitalized for an
272 average of 35 (95% CI: 13-58) days.

273 We further explored the clinical manifestations associated with the Nab (ID_{50} and
274 ID_{90}) levels of the 103 hospitalized patients with COVID-19, and we did not
275 identify any association between the production of Nab titers and the main
276 comorbidities such as arterial hypertension, diabetes, or obesity. However,
277 multivariate analysis showed that anosmia and ageusia ($P<0.01$) were
278 associated with higher Nab titers. All patients with anosmia or ageusia had
279 detectable Nab titers (Figure 1). The Nab GMT of patients who did not have
280 anosmia [32.2 (95% CI: 25-42)] or ageusia [31.7 (95% CI: 24-41)] was lower than
281 that of patients who had anosmia [123 (95% CI: 28-536)] or ageusia [187 (95%
282 CI: 40-869)].

283 To analyze other relevant clinical factors associated with Nabs, we investigated
284 the hospitalization time in relation to initial Nab production on the first hospital
285 day. We stratified the samples into two groups: 50 (48.6%) patients who stayed
286 for up to 14 days and 53 (51.4%) patients who stayed for more than 14 days. We
287 found significantly lower psV SARS-CoV-2 Nab ID_{50} reciprocal plasma dilutions
288 among patients hospitalized for more than 14 days ($\log FC=0.34$; $P=0.024$) than
289 among those with shorter hospitalization stays (Figure 2). The anti-SARS-CoV-2

290 Nab titer of patients with less than 14 days to hospital discharge [GMT=422 (95%
291 CI: 341-2014)] was significantly higher than that of patients with more than 14
292 days to hospital discharge [GMT=149 (95% CI: 32-1687)] ($P<0.05$).

293 To better understand the role of humoral immunity against SARS-CoV-2
294 infection, we analyzed the dynamics of changes in the Nab response initially at
295 14 days post-hospitalization (D14) compared to those obtained at hospital
296 admission (D1). As shown in Figure 3A, plasma samples from D14 were available
297 for 39 (73.5%) of the 53 patients who had longer hospital stays (>14 days). There
298 was a significant increase ($P=0.0190$) in Nab titers (ID_{50}) between D1 [GMT=95
299 (95% CI: 57-158)] and D14 [GMT=251 (95% CI: 178-354)].

300 Patients who were discharged from the hospital were invited to return to the
301 INI/FIOCRUZ after seven months for a new blood collection and clinical follow-
302 up. We performed the Nab assay at this point, hereby called D300, as it was the
303 average day after hospital admission. In this analysis, we compared the Nab titers
304 (ID_{50}) of D1 and D300 for the 60 patients who returned for the study, and we
305 observed an increased progression and persistence in the production of Nabs
306 among these SARS-CoV-2-infected and unvaccinated individuals. The GMT for
307 D1 was 136 (95% CI: 94-197), and the GMT for D300 was 219 (95% CI: 149-
308 321) ($P=0.0232$) (Figure 3B).

309 It was possible to compare D1, D14, and D300 for only 13 patients, and we
310 observed the following values of Nab D1 (ID_{50}) GMT=108 (95% CI: 44-266); Nab
311 D14 (ID_{50}) GMT=219 (95% CI: 120-400) and Nab D300 (ID_{50}) GMT=317 (95%
312 CI: 161-624), ($P=0.0123$ for D1 versus D300; $P=0.0165$ for D14 versus D300)
313 (Figure 3C).

314 Additionally, we evaluated the geometric mean titers of the anti-SARS-CoV-2
315 Nab ID₅₀ of the 15 COVID-19 patients living with HIV-1 (PLWH/COVID-19)
316 included in our study group and compared it with HIV-negative COVID-19
317 patients. The PLWH/COVID-19 participants [(GMT=148 (95% CI: 54-407)]
318 showed no differences in anti-SARS-CoV-2 Nab production when compared to
319 individuals without HIV-1 infection (GMT=222 (95% CI: 153-321), $P=0.950$
320 (Figure 4). As a control, we also performed an HIV-1 PNA to determine the anti-
321 HIV Nab titers of the PLWH/COVID-19 participants on antiretroviral therapy. A
322 high anti-HIV-1 antibody GMT of 583.9 (95% CI: 344-990) was detected,
323 demonstrating maintenance of anti-HIV-1 antibody production in individuals with
324 HIV-1 hospitalized for COVID-19.

325 **4. Discussion**

326 Age is one of the most important prognostic factors associated with lethality in
327 SARS-CoV-2 infection (11). However, in our study, which included hospitalized
328 patients with moderate to severe COVID-19, age was not shown to be a
329 determining factor for the production or magnitude of anti-SARS-CoV-2 Nabs in
330 adults. In the population evaluated, we observed that 55% of those hospitalized
331 patients were men, the mean age was 57 years, and the mortality rate was 33%.
332 The same was observed in the SIVEP-Gripe study, where 678,235 patients were
333 admitted to Brazilian hospitals and showed a mean age of 59 years and 35%
334 mortality (12). Perazzo et al., 2022, in a prospective multicenter study (RECOV-
335 ER-SUS) that assessed hospital mortality, analyzed a cohort that included 1,589
336 participants and found that 54.5% of those admitted were men aged 62 and that
337 27.0% died during hospitalization (13). The sociodemographic characteristics of
338 the population of our study reflect the data presented by Zeiser et al., 2022 and

339 Perazzo et al., 2022, indicating a consensus on the profile of hospitalized patients
340 with COVID-19 in Brazil. Most men are aged between 50 and 60 years and have
341 approximately 30% mortality.

342 The most frequent comorbidities observed in our study were hypertension,
343 diabetes, and obesity. Hypertension is more frequent among elderly individuals
344 and subjects affected by other comorbidities (14). In a multivariate analysis after
345 adjustment for age and other cardiovascular risk factors, hypertension did not
346 play an independent role in COVID-19 development (15). Our study observed
347 similar anti-SARS-CoV-2 Nab titers between groups with and without these main
348 COVID-19 comorbidities. However, the survey by Karuna et al., 2021 noted that
349 hypertension was independently associated with low Nab titers (16). According
350 to some researchers, more than half of COVID-19 patients experienced
351 hyperglycemia, and approximately 33% developed diabetic ketoacidosis (17).
352 Marchand et al., 2020 were the first to observe an increased risk of type 1
353 diabetes development among patients with COVID-19 (18). In our study, the
354 proportion of diabetes patients was 31%, but the presence of diabetes was not
355 related to the ability to produce Nabs, similar to the results observed by Dispinseri
356 et al., 2021 (19).

357 We observed a correlation between anosmia and ageusia with high Nab titers.
358 The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS)
359 released the COVID-19 Anosmia Reporting Tool for Clinicians, which revealed
360 that anosmia was noted in 73% of COVID-19 cases and was the presenting
361 symptom in 26.6% of cases (20). The incidence of anosmia among COVID-19
362 patients, however, varies in different studies. According to a meta-analysis by
363 Tong et al., 2020, the prevalence of olfactory dysfunction among COVID-19

364 patients was estimated to be 52% (21). This variability could be due to genetic
365 factors, viral load (cases of viral damage), specificities of the different evaluated
366 populations, or antibody complexes. However, this last concept must be explored
367 since we found higher Nab titers among patients with anosmia. For example,
368 anosmia is one of the first clinical signs of some neurodegenerative diseases,
369 such as Parkinson's and Alzheimer's diseases. IgG deposits are found in
370 dopaminergic neurons in these patients, suggesting that neurons may be targets
371 for these immunoglobulins (22). In addition, changes in the blood–brain barrier
372 due to inflammation may facilitate the entry of IgG (23). Jae-Hoon Ko. et al. (2020)
373 evaluated 15 asymptomatic patients who presented only anosmia, and the
374 production of Nabs was observed in 80.0% of patients (24). However, the
375 underlying biological basis of anosmia remains obscure, and our study has some
376 limitations. First, our cohort was limited to hospitalized patients, and the results
377 could be different among people with SARS-CoV-2 infection with mild symptoms.
378 Most hospitalized patients had positive Nab titers (88%) with, on average, nine
379 days of symptoms. Other studies also observed the presence of antibodies in
380 acute infection, with a negativity range in 10-25% of patients (25, 26). Notably,
381 seven out of 12 (58%) recovered patients had Nab titers that were under the
382 detectable level, suggesting that other immune responses may have contributed
383 to the recovery of these patients. Previous studies have suggested that cellular
384 immunity can mitigate severe infection, and T cells display strong cross-reactivity
385 to SARS-CoV-2 (27). Whether these patients with COVID-19 without Nabs have
386 a high risk of rebound or reinfection or a poor response to vaccination should be
387 explored in further studies. Our data revealed that individuals who recovered from
388 COVID-19 experienced relatively robust antibody responses to SARS-CoV-2

389 PNA in the acute infection phase. However, patients who arrived at the COVID-
390 19 hospital center with a moderate to critical condition and had low titers
391 remained hospitalized for more than 14 days, and 92.5% needed ventilatory
392 support. Therefore, contrary to what we expected, these patients who initially
393 showed a low neutralizing response did not show milder clinical characteristics,
394 such as the asymptomatic individuals with lower antibodies, as seen in other
395 studies (28, 29).

396 Analysis of the humoral response across multiple cohorts of COVID-19 patients
397 showed that a natural SARS-CoV-2 infection can elicit Nabs in most cases, but
398 accumulating evidence indicates that the magnitude of the response varies
399 greatly among individuals (30, 31). It is still unclear what interferes with the ability
400 to produce potent Nabs. However, it has been observed that plasmablast
401 expansion without somatic hypermutation during the acute phase of COVID-19
402 plays an important role in the early production of Nabs, which may reflect
403 preexisting B repertoire memory (32).

404 We observed that after 14 days of hospitalization, Nab GMTs increased in relation
405 to D1, as observed in other cohorts, where the kinetics of Nab induction were
406 reported to be similar for immunoglobulin seroconversion (31). Patients who died
407 of COVID-19 were also able to increase antibody production at D14; however,
408 this delay in the initial immune response may have facilitated the expansion of
409 the viral load, leading to prolonged hospital stays and/or death. Some clinical
410 studies that have adopted the use of convalescent plasma or monoclonal
411 antibodies have observed patient improvement if administered at the beginning
412 of infection (33), and when the serum is administered late (28 days), there was
413 no improvement in the patient (34). The testing of Nabs in the acute phase of

414 COVID-19 can be a great ally for decision-making in clinical trials of convalescent
415 plasma administration as therapy. Another aspect that corroborates the use of
416 Nab identification and not just IgG titration is the presence of antibody-dependent
417 enhancement (ADE), which may be involved in the clinical observation of
418 increased severity of symptoms associated with early high levels of SARS-CoV-
419 2 antibodies in patients (35).

420 The most extensive study on HIV/COVID-19 coinfection is from a Western Cape,
421 South Africa cohort. PLWH who contracted SARS-CoV-2 died at 2.39 times the
422 rate of patients without HIV with COVID-19. However, HIV was a minor risk factor
423 for severe COVID-19 compared with comorbidities such as cardiopulmonary
424 diseases (36). In our analysis of the production ability of anti-HIV and anti-SARS-
425 CoV-2 antibodies among coinfecting patients, we did not observe differences in
426 relation to the mono-infected group (SARS-CoV-2), indicating that HIV-1 is not
427 an aggravating factor for COVID-19 in terms of humoral responsiveness, but we
428 also observed that a low titer of antibodies resulted in a longer hospitalization.
429 Mishra et al., 2021 observed that some HIV-1 Nabs recognize viral glycan shields
430 of SARS-CoV-2, showing cross-reactivity with SARS-CoV-2 (37). How much the
431 polyclonal cross-neutralizing antibody response can contribute to the
432 improvement of the patient has not yet been elucidated; however, in this study,
433 we verified that a potent neutralizing humoral response at the beginning of the
434 infection is associated with a faster recovery.

435 All protection mechanisms of COVID-19 are not yet clear; however, Nabs are
436 considered a significant correlate of protective immunity and vaccine success,
437 and it has been shown that the rate of SARS-CoV-2 infections among vaccinated
438 individuals is lower among individuals with high Nab levels (38). Extensive efforts

439 to understand the relationship between SARS-CoV-2 and the immune system
440 have highlighted Nab detection assays as essential for screening for potent
441 antibodies for future immunotherapeutic designs. Here, we showed an important
442 relationship between the rapid production of Nabs and shorter hospital stays
443 among patients with moderate and severe COVID-19.

444

445 **Author Contributions:**

446 Conceptualization, DVA and MGM ; Data curation, MGM, MSBQ, MPR, SWC,
447 BGJG and VGSV; Formal analysis, DVA, MSBQ and MRA; Funding acquisition,
448 DVA, BGJG, VGSV and MGM; Investigation, DVA, LM, CBWG, FHC, MLG, JHP,
449 NBRS, MRA, LEC, KMG, MPR, SWC, BGJG, VGSV and MGM; Methodology,
450 DVA, PAC, TFBF, MGAS, CBWG, FHC, NBRS and ASC; Project administration,
451 DVA and MGM; Resources, LM, CBWG, FHC, MGM; Supervision, DVA, NBRS,
452 CBWG, MGM, VGSV, BGJG; Visualization, PAC, TFBF, MGAS, JHP, ASC, LRG,
453 SWC, LEC, KMG, VGSV and MGM; Writing – original draft, DVA; Writing –
454 review & editing, MGM, CBWG, NDS, MSBQ, ASC, MRA.

455 **Funding:**

456 The study was supported by the Fundação Carlos Chagas Filho de Amparo à
457 Pesquisa do Estado do Rio de Janeiro (FAPERJ) (Grant numbers SEI-
458 260003/013002/2021) and INOVA FIOCRUZ/Fundação Oswaldo Cruz (Grant
459 numbers SEI-25380.001587/2020-20).

460 **Institutional Review Board Statement:**

461 The study was conducted in accordance with the Declaration of Helsinki and
462 approved by the Ethics Committee of National Institute of Infectology Evandro
463 Chagas (INI)/ Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil,

464 under the approval number CAAE 32449420.4.1001.5262. All participants or their
465 legal representatives signed an informed consent form prior to enrollment in the
466 study.

467 **Acknowledgments:**

468 The authors are thankful to all patients who agreed to participate in this study,
469 the frontline health care workers at INI/FIOCRUZ Hospital, and the RECOVER
470 study team in Rio de Janeiro. Acknowledgment for publications should read “The
471 following reagent was obtained through the NIH HIV Reagent Program, Division
472 of AIDS, NIAID, NIH: TZM-bl Cells, ARP-8129, contributed by Dr. John C.
473 Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.”

474 **Conflicts of Interest:** The authors declare that the research was conducted in
475 the absence of any commercial or financial relationships that could be construed
476 as a potential conflict of interest. The funders had no role in the design of the
477 study; in the collection, analyses, or interpretation of data; in the writing of the
478 manuscript; or in the decision to publish the results.

479

480 **5. References:**

- 481 1 Tufa Abdisa, Gebremariam Tewodros Haile, Manyazewal Tsegahun, Getinet
482 Tewodros, Webb Dominic-Luc, Hellström M, et al. Inflammatory mediators’
483 profile in patients hospitalized with COVID-19: A comparative study 2022.
484 Front. Immunol., 25 July 2022. Doi: 10.3389/fimmu.2022.964179.
- 485 2 Yin Shengxia, Tong Xin, Huang Aijun, Shen Han, Li Yang, Liu Yong, et al.
486 Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of
487 a COVID-19 patient. Journal of Infection 2020; 81(3): e31–2. Doi:
488 10.1016/j.jinf.2020.06.076.

- 489 3 Garcia-Beltran Wilfredo F., Lam Evan C., Astudillo Michael G., Yang Diane,
490 Miller Tyler E., Feldman Jared, et al. COVID-19-neutralizing antibodies
491 predict disease severity and survival. *Cell* 2021;184(2):476-488.e11. Doi:
492 10.1016/J.CELL.2020.12.015.
- 493 4 Robbiani Davide F., Gaebler Christian, Muecksch Frauke, Lorenzi Julio C.C.,
494 Wang Zijun, Cho Alice, et al. Convergent antibody responses to SARS-CoV-
495 2 in convalescent individuals. *Nature* 2020 584:7821 2020;584(7821):437–
496 42. Doi: 10.1038/s41586-020-2456-9.
- 497 5 Luo Huanle, Jia Tingting, Chen Jiamin, Zeng Shike, Qiu Zengzhao, Wu Shu,
498 et al. The Characterization of Disease Severity Associated IgG Subclasses
499 Response in COVID-19 Patients. *Front Immunol* 2021; 12:460. Doi:
500 10.3389/FIMMU.2021.632814/BIBTEX.
- 501 6 Richardson Safiya, Hirsch Jamie S., Narasimhan Mangala, Crawford James
502 M., McGinn Thomas, Davidson Karina W., et al. Presenting Characteristics,
503 Comorbidities, and Outcomes among 5700 Patients Hospitalized with
504 COVID-19 in the New York City Area. *JAMA - Journal of the American
505 Medical Association* 2020;323(20):2052–9. Doi: 10.1001/JAMA.2020.6775.
- 506 7 Western Cape Department of Health in collaboration with the National
507 Institute for Communicable Diseases South Africa, Boulle Andrew, Davies
508 Mary-Ann, Hussey Hannah, Ismail Muzzammil, Morden Erna, et al. Risk
509 Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population
510 Cohort Study from the Western Cape Province, South Africa. *Clinical
511 Infectious Diseases* 2021;73(7): e2005–15. Doi: 10.1093/CID/CIAA1198.
- 512 8 Deshpande Gururaj Rao, Sapkal Gajanan N., Tilekar Bipin N., Yadav Pragya
513 D., Gurav Yogesh, Gaikwad Shivshankar, et al. Neutralizing antibody

- 514 responses to SARS-CoV-2 in COVID-19 patients. *Indian J Med Res*
515 2020;152(1 & 2):82–7. Doi: 10.4103/IJMR.IJMR_2382_20.
- 516 9 van de Veerdonk Frank L., Giamarellos-Bourboulis Evangelos, Pickkers
517 Peter, Derde Lennie, Leavis Helen, van Crevel Reinout, et al. A guide to
518 immunotherapy for COVID-19. *Nat Med* 2022;28(1):39–50. Doi:
519 10.1038/S41591-021-01643-9.
- 520 10 Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu
521 HY, Tortorici MA, Veesler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom
522 JD. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-
523 CoV-2 Spike Protein for Neutralization Assays. *Viruses*. 2020 May
524 6;12(5):513. doi: 10.3390/v12050513. PMID: 32384820; PMCID:
525 PMC7291041.
- 526 11 Richardson Safiya, Hirsch Jamie S., Narasimhan Mangala, Crawford James
527 M., McGinn Thomas, Davidson Karina W., et al. Presenting Characteristics,
528 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With
529 COVID-19 in the New York City Area. *JAMA* 2020; 323(20):2052–9. Doi:
530 10.1001/JAMA.2020.6775.
- 531 12 Zeiser Felipe André, Donida Bruna, da Costa Cristiano André, Ramos Gabriel
532 de Oliveira, Scherer Juliana Nichterwitz, Barcellos Nêmora Tregnago, et al.
533 First and second COVID-19 waves in Brazil: A cross-sectional study of
534 patients' characteristics related to hospitalization and in-hospital mortality.
535 *Lancet Regional Health Americas* 2022; 6:100107. Doi:
536 10.1016/J.LANA.2021.100107.
- 537 13 Perazzo Hugo, Cardoso Sandra W., Ribeiro Maria Pia D., Moreira Rodrigo,
538 Coelho Lara E., Jalil Emilia M., et al. In-hospital mortality and severe

- 539 outcomes after hospital discharge due to COVID-19: A prospective
540 multicenter study from Brazil. *Lancet Regional Health Americas* 2022;
541 11:100244. Doi: 10.1016/J.LANA.2022.100244.
- 542 14 Farheen Saba, Agrawal Sudhanshu, Zubair Swaleha, Agrawal Anshu, Jamal
543 Fauzia, Altaf Ishrat, et al. Patho-Physiology of Aging and Immune-
544 Senescence: Possible Correlates With Comorbidity and Mortality in Middle-
545 Aged and Old COVID-19 Patients. *Frontiers in Aging* 2021; 2. Doi:
546 10.3389/FRAGI.2021.748591.
- 547 15 Iaccarino Guido, Grassi Guido, Borghi Claudio, Ferri Claudio, Salvetti
548 Massimo, Volpe Massimo M. Age and Multimorbidity Predict Death Among
549 COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of
550 Hypertension. *Hypertension* 2020; 76(2). Doi:
551 10.1161/HYPERTENSIONAHA.120.15324.
- 552 16 Karuna Shelly, Li Shuying Sue, Grant Shannon, Walsh Stephen R., Frank
553 Ian, Casapia Martin, et al. Neutralizing antibody responses over time in
554 demographically and clinically diverse individuals recovered from SARS-
555 CoV-2 infection in the United States and Peru: A cohort study. *PLoS Med*
556 2021;18(12). Doi: 10.1371/JOURNAL.PMED.1003868.
- 557 17 Thaweerat Wajana. Current evidence on pancreatic involvement in SARS-
558 CoV-2 infection. *Pancreatology* 2020;20(5):1013. Doi:
559 10.1016/J.PAN.2020.05.015.
- 560 18 Marchand Lucien, Pecquet Matthieu, Luyton Cédric. Type 1 diabetes onset
561 triggered by COVID-19. *Acta Diabetol* 2020;57(10):1265. Doi:
562 10.1007/S00592-020-01570-0.

- 563 19 Dispinseri Stefania, Lampasona Vito, Secchi Massimiliano, Cara Andrea,
564 Bazzigaluppi Elena, Negri Donatella, et al. Robust Neutralizing Antibodies to
565 SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19
566 Pneumonia. *J Clin Endocrinol Metab* 2021;106(5):1472–81. Doi:
567 10.1210/CLINEM/DGAB055.
- 568 20 Kaye Rachel, Chang C. W.David, Kazahaya Ken, Brereton Jean, Denny
569 James C. COVID-19 Anosmia Reporting Tool: Initial Findings.
570 *Otolaryngology - Head and Neck Surgery (United States)* 2020; 163(1):132–
571 4. Doi: 10.1177/0194599820922992.
- 572 21 Tong Jane Y., Wong Amanda, Zhu Daniel, Fastenberg Judd H., Tham
573 Tristan. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19
574 Patients: A Systematic Review and Meta-analysis. *Otolaryngol Head Neck*
575 *Surg* 2020; 163(1):3–11. Doi: 10.1177/0194599820926473.
- 576 22 Doty Richard L., Hawkes Christopher H. Chemosensory dysfunction in
577 neurodegenerative diseases. *Handb Clin Neurol* 2019;164:325–60. Doi:
578 10.1016/B978-0-444-63855-7.00020-4.
- 579 23 Erickson Michelle A., Banks William A. Neuroimmune Axes of the Blood-
580 Brain Barriers and Blood-Brain Interfaces: Bases for Physiological
581 Regulation, Disease States, and Pharmacological Interventions. *Pharmacol*
582 *Rev* 2018;70(2):278–314. Doi: 10.1124/PR.117.014647.
- 583 24 Ko Jae Hoon, Joo Eun Jeong, Park Su Jin, Baek Jin Yang, Kim Won Duk,
584 Jee Jaehwan, et al. Neutralizing Antibody Production in Asymptomatic and
585 Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients.
586 *J Clin Med* 2020;9(7):1–13. Doi: 10.3390/JCM9072268.

- 587 25 Wang Hongye, Yan Dongshan, Li Ya, Gong Yanfei, Mai Yulin, Li Bingxiang,
588 et al. Clinical and antibody characteristics reveal diverse signatures of severe
589 and non-severe SARS-CoV-2 patients. *Infect Dis Poverty* 2022; 11(1):1–15.
590 Doi: 10.1186/S40249-022-00940-W/FIGURES/7.
- 591 26 Wu Fan, Wang Aojie, Liu Mei, Wang Qimin, Chen Jun, Xia Shuai, et al.
592 Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered
593 patient cohort and their implications. *MedRxiv* 2020:2020.03.30.20047365.
594 Doi: 10.1101/2020.03.30.20047365.
- 595 27 le Bert Nina, Tan Anthony T, Kunasegaran Kamini, Tham Christine Y L,
596 Hafezi Morteza, Chia Adeline, et al. SARS-CoV-2-specific T cell immunity in
597 cases of COVID-19 and SARS, and uninfected controls. *Nature*
598 2020;584:457. Doi: 10.1038/s41586-020-2550-z.
- 599 28 Brochot Etienne, Demey Baptiste, Touzé Antoine, Belouzard Sandrine,
600 Dubuisson Jean, Schmit Jean-Luc, et al. Anti-Spike, anti-Nucleocapsid and
601 neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers.
602 *MedRxiv* 2020:2020.05.12.20098236. Doi: 10.1101/2020.05.12.20098236.
- 603 29 Long Quan Xin, Tang Xiao Jun, Shi Qiu Lin, Li Qin, Deng Hai Jun, Yuan Jun,
604 et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2
605 infections. *Nature Medicine* 2020 26:8 2020;26(8):1200–4. Doi:
606 10.1038/s41591-020-0965-6.
- 607 30 Dispinseri Stefania, Secchi Massimiliano, Pirillo Maria Franca, Tolazzi
608 Monica, Borghi Martina, Brigatti Cristina, et al. Neutralizing antibody
609 responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and
610 critical for survival. *Nature Communications* 2021 12:1 2021;12(1):1–12. Doi:
611 10.1038/s41467-021-22958-8.

- 612 31 Cheng Meng Li, Liu Hui Ying, Zhao Hui, Wang Guo Qing, Zhou Chao, Zheng
613 Jing, et al. Longitudinal dynamics of antibody responses in recovered COVID-
614 19 patients. *Signal Transduct Target Ther* 2021; 6(1). Doi: 10.1038/S41392-
615 021-00559-7.
- 616 32 Unterman Avraham, Sumida Tomokazu S., Nouri Nima, Yan Xiting, Zhao
617 Amy Y., Gasque Victor, et al. Single-cell multi-omics reveals dyssynchrony
618 of the innate and adaptive immune system in progressive COVID-19. *Nat*
619 *Commun* 2022;13(1). Doi: 10.1038/S41467-021-27716-4.
- 620 33 Tiberghien Pierre, de Lamballerie Xavier, Morel Pascal, Gallian Pierre,
621 Lacombe Karine, Yazdanpanah Yazdan. Collecting and evaluating
622 convalescent plasma for COVID-19 treatment: why and how? *Vox Sang*
623 2020; 115(6):488–94. Doi: 10.1111/VOX.12926.
- 624 34 O'Donnell Max R., Grinsztejn Beatriz, Cummings Matthew J., Justman
625 Jessica E., Lamb Matthew R., Eckhardt Christina M., et al. A randomized
626 double-blind controlled trial of convalescent plasma in adults with severe
627 COVID-19. *J Clin Invest* 2021; 131(13). Doi: 10.1172/JCI150646.
- 628 35 Okuya Kosuke, Hattori Takanari, Saito Takeshi, Takadate Yoshihiro, Sasaki
629 Michihito, Furuyama Wakako, et al. Multiple Routes of Antibody-Dependent
630 Enhancement of SARS-CoV-2 Infection. *Microbiol Spectr* 2022; 10(2). Doi:
631 10.1128/SPECTRUM.01553-21.
- 632 36 Boulle Andrew, Davies Mary Ann, Hussey Hannah, Ismail Muzzammil,
633 Morden Erna, Vundle Ziyanda, et al. Risk Factors for Coronavirus Disease
634 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape
635 Province, South Africa. *Clin Infect Dis* 2021;73(7): E2005–15. Doi:
636 10.1093/CID/CIAA1198.

- 637 37 Mishra N, Kumar S, Singh S, Bansal T, Jain N, Saluja S, Kumar R,
638 Bhattacharyya S, Palanichamy JK, Mir RA, Sinha S, Luthra K. Cross-
639 neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing
640 antibodies and polyclonal plasma. PLoS Pathog. 2021 Sep 24;17(9):
641 e1009958. doi: 10.1371/journal.ppat.1009958. PMID: 34559854; PMCID:
642 PMC8494312.
- 643 38 Plotkin Stanley A. Vaccines: correlates of vaccine-induced immunity. Clin
644 Infect Dis 2008;47(3):401–9. Doi: 10.1086/589862.
- 645

646 Table 1. Sociodemographic characteristics of study participants.

Characteristics		Hospitalization Stay Days			P-value
		Overall	1-14	>14	
Total		103 (100%)	50 (48.6%)	53 (51.4%)	
Gender	Male	57 (55.3%)	28 (56%)	29 (54.7%)	1
	Female	46 (44.7%)	22 (44%)	24 (45.3%)	
Skin Color	Brown	71 (68.9%)	30 (60%)	41 (77.4%)	0.032
	White	14 (13.6%)	6 (12%)	8 (15.1%)	
	Black	8 (7.8%)	5 (10%)	3 (5.7%)	
	Unk	10 (9.7%)	9 (18%)	1 (1.9%)	
State of Origin	RJ	101 (98.1%)	49 (98%)	52 (98.1%)	1
	AM	2 (1.9%)	1 (2%)	1 (1.9%)	
Schooling	High school	42 (40.8%)	23 (46%)	19 (35.8%)	0.587
	Elementary School	20 (19.4%)	8 (16%)	12 (22.6%)	
	University Education	8 (7.8%)	4 (8%)	4 (7.5%)	
	First grade	22 (21.4%)	10 (20%)	12 (22.6%)	
	Illiterate	11 (10.6%)	5 (10%)	6 (11.5%)	
Age		57.27 (IQR=23.51)	56.37 (IQR=23.59)	57.57 (IQR=25.39)	0.847
Age Category	18-39	18 (17.4%)	5 (10%)	13 (24.5%)	0.045
	40-59	34 (33%)	21 (42%)	13 (24.5%)	
	60-79	45 (43.7%)	23 (46%)	22 (41.5%)	
	80-90	6 (5.9%)	1 (2%)	5 (9.5%)	

647 Values are presented as number (%) or median (interquartile range).

648

649

650


651 Table 2. Clinical characteristics and symptoms of study participants.

Comorbidities	Levels	Overall	Hospitalization days		P-value
			1-14 days	>14 days	
Systemic arterial hypertension	No	54 (52.4%)	24 (48%)	30 (56.6%)	0.499
	Yes	49 (47.6%)	26 (52%)	23 (43.4%)	
Diabetes mellitus	No	70 (68%)	31 (62%)	39 (73.6%)	0.295
	Yes	33 (32%)	19 (38%)	14 (26.4%)	
Chronic obstructive pulmonary disease	No	93 (90.3%)	48 (96%)	45 (84.9%)	0.117
	Yes	10 (9.7%)	2 (4%)	8 (15.1%)	
Cerebrovascular accident	No	101 (98.1%)	50 (100%)	51 (96.2%)	0.501
	Yes	2 (1.9%)	0 (0%)	2 (3.8%)	
Cardiovascular failure	No	99 (96.1%)	48 (96%)	51 (96.2%)	1
	Yes	4 (3.9%)	2 (4%)	2 (3.8%)	
Coronary heart disease	No	102 (99%)	49 (98%)	53 (100%)	0.977
	Yes	1 (1%)	1 (2%)	0 (0%)	
Active cancer	No	103 (100%)	50 (100%)	53 (100%)	0.768
Chronic Kidney Disease (on dialysis)	No	102 (99%)	50 (100%)	52 (98.1%)	1
	Yes	1 (1%)	0 (0%)	1 (1.9%)	
Rheumatic Diseases	No	102 (99%)	49 (98%)	53 (100%)	0.977
	Yes	1 (1%)	1 (2%)	0 (0%)	
Dementia	No	102 (99%)	50 (100%)	52 (98.1%)	1
	Yes	1 (1%)	0 (0%)	1 (1.9%)	
Obesity or previous bariatric surgery	No	84 (81.6%)	41 (82%)	43 (81.1%)	1
	Yes	19 (18.4%)	9 (18%)	10 (18.9%)	
Current smoking	No	96 (93.2%)	49 (98%)	47 (88.7%)	0.137
	Yes	7 (6.8%)	1 (2%)	6 (11.3%)	
Active tuberculosis	No	99 (96.1%)	48 (96%)	51 (96.2%)	1
	Yes	4 (3.9%)	2 (4%)	2 (3.8%)	
Tuberculosis treated	No	102 (99%)	49 (98%)	53 (100%)	0.977
	Yes	1 (1%)	1 (2%)	0 (0%)	
Hepatic cirrhosis	No	102 (99%)	50 (100%)	52 (98.1%)	1
	Yes	1 (1%)	0 (0%)	1 (1.9%)	
Transplant	No	103 (100%)	50 (100%)	53 (100%)	0.768
HIV serological status	Negative	88 (85.4%)	45 (90%)	43 (81.1%)	0.101
	Positive	15 (14.6%)	5 (10%)	10 (18.9%)	
Clinical data during COVID-19					
Fever	No	51 (49.5%)	26 (52%)	25 (47.2%)	0.77
	Yes	52 (50.5%)	24 (48%)	28 (52.8%)	
Oxygen Saturation Below 95 %	No	63 (61.2%)	33 (66%)	30 (56.6%)	0.438
	Yes	40 (38.8%)	17 (34%)	23 (43.4%)	
Cough	No	40 (38.8%)	19 (38%)	21 (39.6%)	1
	Yes	63 (61.2%)	31 (62%)	32 (60.4%)	
Chest Pain	No	99 (96.1%)	48 (96%)	51 (96.2%)	1
	Yes	4 (3.9%)	2 (4%)	2 (3.8%)	
Coryza	No	97 (94.2%)	47 (94%)	50 (94.3%)	1
	Yes	6 (5.8%)	3 (6%)	3 (5.7%)	
Dyspnea	No	26 (25.2%)	14 (28%)	12 (22.6%)	0.69
	Yes	77 (74.8%)	36 (72%)	41 (77.4%)	
Odynophagy	No	103 (100%)	50 (100%)	53 (100%)	0.768
Anosmia	No	95 (92.2%)	45 (90%)	50 (94.3%)	0.65

Odynophagy	Yes	8 (7.8%)	5 (10%)	3 (5.7%)	
Ageusia	No	96 (93.2%)	47 (94%)	49 (92.5%)	1
	Yes	7 (6.8%)	3 (6%)	4 (7.5%)	
Diarrhea	No	95 (92.2%)	46 (92%)	49 (92.5%)	1
	Yes	8 (7.8%)	4 (8%)	4 (7.5%)	
Abdominal Pain	No	100 (97.1%)	49 (98%)	51 (96.2%)	1
	Yes	3 (2.9%)	1 (2%)	2 (3.8%)	
Nausea	No	99 (96.1%)	49 (98%)	50 (94.3%)	0.652
	Yes	4 (3.9%)	1 (2%)	3 (5.7%)	
Headache	No	92 (89.3%)	45 (90%)	47 (88.7%)	1
	Yes	11 (10.7%)	5 (10%)	6 (11.3%)	
Myalgia	No	82 (79.6%)	39 (78%)	43 (81.1%)	0.881
	Yes	21 (20.4%)	11 (22%)	10 (18.9%)	
Some Thrombosis	No	103 (100%)	50 (100%)	53 (100%)	0.768
Oxygen Supplementation or Ventilatory Support	No	20 (19.4%)	16 (32%)	4 (7.5%)	0.004
WHO Clinical Progression Scale	Yes	83 (80.6%)	34 (68%)	49 (92.5%)	
	WHO Scale	8 (IQR=0)	8 (IQR=0)	8 (IQR=0)	0.511
Glasgow Scale	Glasgow Scale	15 (IQR=0)	15 (IQR=0)	15 (IQR=0)	0.321
	SOFA	3 (IQR=4)	2.5 (IQR=3)	5 (IQR=5)	0.01
SAPS3	SAPS3	48 (IQR=19)	45 (IQR=17)	49 (IQR=15)	0.048
Outcome	Discharge	69 (67%)	37 (74%)	32 (60.4%)	0.208
	Death	34 (33%)	13 (26%)	21 (39.6%)	

652 Values are presented as number (%) or median (interquartile range).

653




654

655

656 Figure 1: Clinical symptoms of anosmia and ageusia of SARS-CoV-2 infection are
657 influenced by neutralizing antibody titers. The COVID-19 patients (n = 103) were
658 divided into groups according to the presence or absence of these symptoms and
659 analyzed for their Nab titers with 90% inhibition (ID₉₀). The bar line represents the
660 geometric mean with a 95% confidence interval. For each parameter, a
661 nonparametric ANOVA (Sidak's multiple comparisons test) was performed;
662 statistical significance is indicated with the following notation: $P < 0.001$.

663




665

666 Figure 2: PsV SARS-CoV-2 neutralizing antibody ID₅₀ reciprocal plasma dilutions
667 and hospitalization stay (in days). The sample distributions of data are
668 represented in box plots and strip plots in gray. In black, the center circle
669 represents the expected mean marginal effect for each group estimated from
670 linear multiple fixed effects models. The fixed effects were adjusted by age, sex,
671 self-declared race, number of comorbidities, and days since the first symptoms
672 of COVID-19 at hospital admission. Black horizontal bars represent the 95%
673 confidence intervals of the expected mean marginal effects by group.


674

675 (a)




676

677 (b)



678


679 (c)



680

681 Figure 3: Longitudinal humoral immune response of inpatients with COVID-19. A,
682 Nabs (ID₅₀) of COVID-19 patients at admission D1 compared to the Nab (ID₅₀)
683 assessment 14 days after hospital discharge. B, Nabs (ID₅₀) of COVID-19
684 patients at admission D1 compared to Nab (ID₅₀) assessment 300 days after
685 hospital discharge. C, Changes in Nab titers (ID₅₀) for each patient are shown
686 over time. Data from patients for the first sample D1, after 14 days and the last
687 collected sample D300 are shown.

688



689

690 Figure 4: Neutralizing antibody responses from SARS-CoV-2-infected and HIV-
691 coinfected patients. Nabs during the first day of hospitalization of 85 COVID-19
692 patients not infected with HIV and 15 PLWH coinfecting with SARS-CoV-2
693 (COVID-19/PLWH) are shown. Fifteen patients (COVID-19/PLWH) showed Nab
694 titers against SARS-CoV-2 and HIV-1 pseudovirus. Negative values (titers below
695 20) were considered 10 for calculating the geometric mean titer (GMT). The
696 horizontal bars indicate the GMT, and the bars indicate 95% confidence intervals.